Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.

Xue, Kai; Gu, Juan J; Zhang, Qunling; Mavis, Cory; Hernandez-Ilizaliturri, Francisco J; Czuczman, Myron S; Guo, Ye

Xue, Kai; Gu, Juan J; Zhang, Qunling; Mavis, Cory; Hernandez-Ilizaliturri, Francisco J; Czuczman, Myron S; Guo, Ye.

Affiliation

Xue K; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Gu JJ; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Zhang Q; Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA.
Mavis C; Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Hernandez-Ilizaliturri FJ; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China.
Czuczman MS; Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA.
Guo Y; Departments of Medicine and Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA.

J Cancer Res Clin Oncol ; 142(2): 379-87, 2016 Feb.

Article in En | MEDLINE | ID: mdl-26314218

Subject(s)
Key words

Chemotherapy resistance; Histone deacetylase inhibitors; Lymphoma; Vorinostat

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Lymphoma, Large B-Cell, Diffuse / Histone Deacetylase Inhibitors / Rituximab / Hydroxamic Acids / Lymphoma Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: J Cancer Res Clin Oncol Year: 2016 Document type: Article Country of publication: Alemania

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google